Kyowa's Poteligeo meets in Phase III for CTCL

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) said Poteligeo mogamulizumab (AMG 761, KW-0761) met the primary endpoint of improving progression-free survival (PFS) in the Phase III MAVORIC trial to treat mycosis fungoides or

Read the full 328 word article

User Sign In